OnKure Therapeutics, Inc. — Director's Dealing 2021

Aug 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-08-25

Reporting Person: Cruse Michael (Senior VP-Corporate Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-25	Common Stock	P	2500	$7.4464	Acquired	2500	Direct

Footnotes

F1: The weighted average purchase price for the transaction was $7.4464. The shares were purchased at a range of prices between $7.425 and $7.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.